Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
AdCompositiveReplimune immunotherapyOpdivoPositive
AI Analysis
Summary
Replimune's immunotherapy received a positive FDA advisory committee vote (10-3) for advanced melanoma in combination with Bristol Myers Squibb's Opdivo, though the panel raised concerns about trial design during deliberations.
Outcome Details
FDA's Cellular, Tissue and Gene Therapies advisory committee voted 10 to 3 in favor of Replimune's immunotherapy for advanced melanoma in combination with Opdivo
Importance:8/10
Sentiment:
0.75
immunotherapymelanomaFDA advisory committeecombination therapypositive vote
Related Companies
Read the original article
Published by BioSpace on July 30, 2026 10:29 PM